TNGXTango Therapeutics, Inc.Signing up patients
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC · RAS Mutation · MTAP Deletion · Lung Cancer · Pancreatic Cancer Metastatic · Thoracic Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 183 (planned)
- Started
- May 31, 2025
- Main results expected
- Jun 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Maximum Tolerated Dose
Measured over: 21 days
Phase 1: Maximum Tolerated Dose
Measured over: 28 days
Phase 2: Combination Anti-neoplastic Activity
Measured over: 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06922591 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC